

ESENDER_LOGIN:	ENOTICES
CUSTOMER_LOGIN:	ECAS_n0083c8y
NO_DOC_EXT:	2022-194091
SOFTWARE_VERSION:	13.2.0
ORGANISATION:	ENOTICES
COUNTRY:	EU
PHONE:	/
E_MAIL:	notices@kemea-research.gr

LANGUAGE:	EN
CATEGORY:	ORIG
FORM:	F02
VERSION:	R2.0.9.S05
DATE_EXPECTED_PUBLICATION:	/

Contract notice

Services

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

- I.1) **Name and addresses**
Official name: KENTRO MELETON ASFALEIAS (KEMEA)
Postal address: P. KANELLOPOULOU 4
Town: ATHENS
NUTS code: EL30 Αττική / Attiki
Postal code: 10177
Country: Greece
Contact person: Anastasia Tigka
E-mail: a.tigka@kemea-research.gr
Telephone: +30 2107710805
Fax: +30 2111004499
Internet address(es):
Main address: <http://kemea.gr/en/>
- I.1) **Name and addresses**
Official name: DIENST JUSTITIELE INRICHTINGEN (DJI)
Postal address: Turfmarkt 147
Town: Den Haag
NUTS code: NL332 Agglomeratie 's-Gravenhage
Postal code: 30132
Country: Netherlands
E-mail: r.apostol@dji.minjus.nl
Internet address(es):
Main address: <https://www.dji.nl/>
- I.1) **Name and addresses**
Official name: DE FEDERALE OVERHEIDSDIENST JUSTITIE - LE SERVICE PUBLIC FEDERAL JUSTICE (DG-EPI)
Postal address: Waterloolaan 115
Town: BRUSSELS
NUTS code: BE100 Arr. de Bruxelles-Capitale / Arr. Brussel-Hoofdstad
Postal code: 1000
Country: Belgium
Contact person: VAN MALDEREN SARA
E-mail: SARA.VANMALDEREN@just.fgov.be
Internet address(es):
Main address: <https://justitie.belgium.be>
- I.1) **Name and addresses**

Official name: MINISTERIO DEL INTERIOR (ESMIR)

Postal address: Calle Amador de los ríos 7

Town: MADRID

NUTS code: ES30 Comunidad de Madrid

Postal code: 28071

Country: Spain

Contact person: Ángel Vicente López Muriel

E-mail: avicente.lopez@dgip.mir.es

Internet address(es):

Main address: <http://www.interior.gob.es/>

I.2) **Information about joint procurement**

The contract involves joint procurement

In the case of joint procurement involving different countries, state applicable national procurement law:
Greek

I.3) **Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at: <https://drug-detect.eu/>

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: <https://eprocurement.gov.gr>

I.4) **Type of the contracting authority**

Body governed by public law

I.5) **Main activity**

Public order and safety

Section II: Object

II.1) **Scope of the procurement**

II.1.1) **Title:**

'Innovation procurement for Drug Detection in correctional institutions and prisons' — DrugDetect

II.1.2) **Main CPV code**

72000000 IT services: consulting, software development, Internet and support

II.1.3) **Type of contract**

Services

II.1.4) **Short description:**

This contract notice provides information about a public procurement of innovative solutions (PPI) carried out by the project 'Innovation procurement for Drug Detection in correctional institutions and prisons' — DrugDetect. This project receives co-funding by the COSME programme of the European Union under grant agreement No 101036225.

The DrugDetect project aims to procure an innovative solution for the automatic detection of a large range of drugs in correctional institutions and prisons, that is available 24/7, does not cause delays in internal processes, does not require minimal human intervention, and is GDPR compliant.

Following the identified needs and the market analysis, the DrugDetect Buyer's Group decided to pursue 3 Lots during the present procurement procedure:

Lot 1 – Identification of drugs

Lot 2 – Detection of drugs inside packages/luggage and

Lot 3 – Detection of drugs on the body.

- II.1.5) **Estimated total value**
Value excluding VAT: 3 880 000.00 EUR
- II.1.6) **Information about lots**
This contract is divided into lots: yes
Tenders may be submitted for all lots
- II.2) **Description**
- II.2.1) **Title:**
Identification of drugs
Lot No: 1
- II.2.2) **Additional CPV code(s)**
38544000 Drug detection apparatus
- II.2.3) **Place of performance**
NUTS code: BE Belgique / België
NUTS code: EL Ελλάδα / Elláda
- II.2.4) **Description of the procurement:**
The solution proposed by the Tenderer must comprise one or more innovative components or one or more architectural innovations. The Drug Detect procurement does not include the procurement of research and development (R&D).
In particular, the proposed solution must comprise new or significantly improved components or architecture that have already been (partially) demonstrated on a small scale and may be nearly or already available in small quantities on the market, but which have not been widely adopted yet. Typically, owing to the residual risk or market uncertainty, these innovative components or architecture have not been produced at a large enough scale. This also includes existing solutions that are to be utilised in a new and innovative way.
Whether a component or architectural feature is innovative will be assessed by the Drug Detect consortium according to the following three cumulative minimum requirements:
1. The innovative component or architectural innovation must be related to innovation aspects indicated as important for the given lot.
2. The difference in time between first deployment of the device/solution, which is equipped with such a component or is based on such architectural innovations, and the date, when the given Tender was due for submission, must not exceed 24 months.
3. Finally, the component or architectural innovation in question must not have been used for more than 50 clients.
These cumulative minimum requirements will be assessed for each bid submitted. Final Tenders that do not conform to this minimal requirement will be excluded.
In Lot 1, the Buyers' Group is interested in the following innovative features:
Artificial Intelligence to support recognition of substances
Detection without opening a package/luggage
Increase the number of drugs that can be detected
Improved accuracy of detection
Increased speed of detection
Minimal operator interaction
Integration with other relevant functionalities such as air sampling/X-ray/millimeter wave scans
- II.2.5) **Award criteria**
Price is not the only award criterion and all criteria are stated only in the procurement documents
- II.2.6) **Estimated value**

Value excluding VAT: 1 380 000.00 EUR

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 20

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: yes

Identification of the project:

This project receives co-funding by the COSME programme of the European Union under grant agreement No 101036225.

II.2.14) **Additional information**

VAT is included. For details on VAT regime, see Descriptive Document

II.2) **Description**

II.2.1) **Title:**

Detection of drugs inside packages/luggage

Lot No: 2

II.2.2) **Additional CPV code(s)**

38544000 Drug detection apparatus

II.2.3) **Place of performance**

NUTS code: BE Belgique / België

NUTS code: EL Ελλάδα / Ελλάδα

NUTS code: ES España

NUTS code: NL Nederland

II.2.4) **Description of the procurement:**

The solution proposed by the Tenderer must comprise one or more innovative components or one or more architectural innovations. The Drug Detect procurement does not include the procurement of research and development (R&D).

In particular, the proposed solution must comprise new or significantly improved components or architecture that have already been (partially) demonstrated on a small scale and may be nearly or already available in small quantities on the market, but which have not been widely adopted yet. Typically, owing to the residual risk or

market uncertainty, these innovative components or architecture have not been produced at a large enough scale. This also includes existing solutions that are to be utilised in a new and innovative way.

Whether a component or architectural feature is innovative will be assessed by the Drug Detect consortium according to the following three cumulative minimum requirements:

1. The innovative component or architectural innovation must be related to innovation aspects indicated as important for the given lot.
2. The difference in time between first deployment of the device/solution, which is equipped with such a component or is based on such architectural innovations, and the date, when the given Tender was due for submission, must not exceed 24 months.
3. Finally, the component or architectural innovation in question must not have been used for more than 50 clients.

These cumulative minimum requirements will be assessed for each bid submitted. Final Tenders that do not conform to this minimal requirement will be excluded.

In Lot 2, the Buyers' Group is interested in the following innovative features:

Improved resolution to support detection

Improved accuracy of detection

Artificial Intelligence to support recognition of suspicious objects/drugs

Other functionalities that enable easier detection (e.g. marking in colours, alerts etc.)

Improved Threat Image Projection (TIP) or similar software

Integration with other relevant functionalities such as air sampling/trace detection etc.

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

Value excluding VAT: 790 000.00 EUR

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 20

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: yes

Identification of the project:

This project receives co-funding by the COSME programme of the European Union under grant agreement No 101036225.

II.2.14) **Additional information**

VAT is included. For VAT regime, see Descriptive Document

II.2) **Description**

II.2.1) **Title:**

Detection of drugs on the body

Lot No: 3

II.2.2) **Additional CPV code(s)**

38544000 Drug detection apparatus

II.2.3) Place of performance

NUTS code: EL Ελλάδα / Elláda

NUTS code: ES España

NUTS code: NL Nederland

II.2.4) Description of the procurement:

The solution proposed by the Tenderer must comprise one or more innovative components or one or more architectural innovations. The Drug Detect procurement does not include the procurement of research and development (R&D).

In particular, the proposed solution must comprise new or significantly improved components or architecture that have already been (partially) demonstrated on a small scale and may be nearly or already available in small quantities on the market, but which have not been widely adopted yet. Typically, owing to the residual risk or market uncertainty, these innovative components or architecture have not been produced at a large enough scale. This also includes existing solutions that are to be utilised in a new and innovative way.

Whether a component or architectural feature is innovative will be assessed by the Drug Detect consortium according to the following three cumulative minimum requirements:

1. The innovative component or architectural innovation must be related to innovation aspects indicated as important for the given lot.
2. The difference in time between first deployment of the device/solution, which is equipped with such a component or is based on such architectural innovations, and the date, when the given Tender was due for submission, must not exceed 24 months.
3. Finally, the component or architectural innovation in question must not have been used for more than 50 clients.

These cumulative minimum requirements will be assessed for each bid submitted. Final Tenders that do not conform to this minimal requirement will be excluded.

In Lot 3, the Buyers' Group is interested in the following innovative features:

Speed of scanning

Minimal operator interaction

Artificial Intelligence to support recognition of suspicious objects/drugs

Integration with other relevant functionalities such as air sampling/trace detection etc.

Accuracy of detection

Improved detection of feet, hair etc.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: 1 710 000.00 EUR

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 20

This contract is subject to renewal: no

II.2.10) Information about variants

Variants will be accepted: no

II.2.11) Information about options

Options: no

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: yes

Identification of the project:

This project receives co-funding by the COSME programme of the European Union under grant agreement No 101036225.

II.2.14) **Additional information**

VAT is included. For VAT regime, see Descriptive Document

Section III: Legal, economic, financial and technical information

III.1) **Conditions for participation**

III.1.1) **Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers**

List and brief description of conditions:

The Tenderer, the members of the Consortium (if applicable) and the subcontractors (if applicable), should be registered in the Chamber of Commerce of their own country or equivalent.

III.1.3) **Technical and professional ability**

Selection criteria as stated in the procurement documents

Section IV: Procedure

IV.1) **Description**

IV.1.1) **Type of procedure**

Competitive dialogue

IV.1.3) **Information about a framework agreement or a dynamic purchasing system**

IV.1.8) **Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**

Notice number in the OJ S: [2022/S 111-311907](#)

IV.2.2) **Time limit for receipt of tenders or requests to participate**

Date: 10/02/2023

Local time: 15:00

IV.2.3) **Estimated date of dispatch of invitations to tender or to participate to selected candidates**

Date: 12/02/2023

IV.2.4) **Languages in which tenders or requests to participate may be submitted:**

English

IV.2.6) **Minimum time frame during which the tenderer must maintain the tender**

Duration in months: 6 (from the date stated for receipt of tender)

Section VI: Complementary information

VI.1) **Information about recurrence**

This is a recurrent procurement: no

VI.3) **Additional information:**

The contracting authority involved in the DrugDetect project is not legally bound in any way by the outcome of the market consultation. The open market consultation will provide an overview on the procurement objectives, the PPI process and the main clauses of the contract. It is also not part of any pre-qualification or selection process. No advantage or disadvantage will be given to any supplier / group of suppliers to the detriment of

others during the market consultation and the sub-subsequent competitive procedure for the award of contracts procurement.

All communication will be carried out in English via the email drugdetect_procurement@kemea-research.gr

All information provided during the open market consultation and other background information will be published online in English.

VI.4) Procedures for review

VI.4.1) Review body

Official name: Greek Administrative Court of Appeal of Athens

Town: ATHENS

Country: Greece

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures:

The submission of a tender implies unconditional acceptance of all terms and conditions contained in this Call.

Under penalty of exclusion, tenders must not contain any reservation in relation to any point in the Tender terms and conditions.

If the Tenderers have any complaints about the contents of the tendering documents – specifically, but not exclusively, regarding exclusion, selection, pass/fail and weighted award criteria – they must submit them to the Lead Procurer within ten (10) days of the publication of the Call on TED. If the dispute is not solved amicably, the Tenderer may lodge an appeal with the Greek Administrative Court of Appeal of Athens within five (5) days of the decision of the Lead Procurer. Failure to submit an appeal within these deadlines leads to termination of the right to appeal (on a later stage and on other grounds) and to participate in the DrugDetect PPI.

All possible complaints during the tendering process will be solely submitted to the Lead Procurer within ten (10) days following the notification of the final decision – as described in step 7 of section 3.7 - of the CB. Complaints will not be addressed to the other members of the Buyer's Group or the EC.

Submission of complaints shall not lead to unreasonable delays in the evaluation and award procedures.

The Lead procurer, the members of the Buyer's Group and/or the EC will not be liable for any loss or damage that the tenderer may suffer in preparing and submitting a bid for this PPI.

The Lead Procurer will forward the complaints to the EvC which is responsible to evaluate the complaints and to submit its opinion to the CB for final decision.

Possible complaints against any final decision of the CB may be reviewed by the Greek Administrative Court of Appeal of Athens.⁴ The tenderers are mandated to notify the Lead Procurer in writing that they are submitting an appeal to challenge a decision of the CB.

Any dispute or claim arising in connection with the execution of the contracts shall be heard by Greek Administrative Court of Appeal of Athens.

VI.5) Date of dispatch of this notice:

09/12/2022